Media stories about ProPhase Labs (NASDAQ:PRPH) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProPhase Labs earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.6364370432396 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

ProPhase Labs (NASDAQ:PRPH) traded up $0.16 during trading hours on Monday, reaching $2.79. The company’s stock had a trading volume of 42,582 shares, compared to its average volume of 15,079. The stock has a market capitalization of $29.27, a PE ratio of 1.22 and a beta of 0.16. ProPhase Labs has a 1 year low of $1.78 and a 1 year high of $2.85.

ProPhase Labs declared that its board has initiated a stock buyback program on Friday, November 10th that allows the company to repurchase 1,700,000 shares. This repurchase authorization allows the company to buy shares of its stock through a tender offer. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

In other ProPhase Labs news, CEO Ted William Karkus sold 424,789 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $2.30, for a total value of $977,014.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 29.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at

ProPhase Labs Company Profile

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Insider Buying and Selling by Quarter for ProPhase Labs (NASDAQ:PRPH)

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with's FREE daily email newsletter.